Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19167838rdf:typepubmed:Citationlld:pubmed
pubmed-article:19167838lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:19167838lifeskim:mentionsumls-concept:C0555198lld:lifeskim
pubmed-article:19167838lifeskim:mentionsumls-concept:C0796392lld:lifeskim
pubmed-article:19167838lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:19167838lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:19167838lifeskim:mentionsumls-concept:C0729296lld:lifeskim
pubmed-article:19167838pubmed:issue1lld:pubmed
pubmed-article:19167838pubmed:dateCreated2009-8-21lld:pubmed
pubmed-article:19167838pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19167838pubmed:abstractTextPreclinical studies suggest that inhibition of vascular endothelial growth factor (VEGF) improves glioma response to radiotherapy. Bevacizumab, a monoclonal antibody against VEGF, has shown promise in recurrent gliomas, but the safety and efficacy of concurrent bevacizumab with brain irradiation has not been extensively studied. The objectives of this study were to determine the safety and activity of this combination in malignant gliomas.lld:pubmed
pubmed-article:19167838pubmed:languageenglld:pubmed
pubmed-article:19167838pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19167838pubmed:citationSubsetIMlld:pubmed
pubmed-article:19167838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19167838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19167838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19167838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19167838pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19167838pubmed:statusMEDLINElld:pubmed
pubmed-article:19167838pubmed:monthSeplld:pubmed
pubmed-article:19167838pubmed:issn1879-355Xlld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:AbreyLauren...lld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:GutinPhilip...lld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:YamadaYoshiya...lld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:ChangJenghwaJlld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:KarimiSasanSlld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:HouBob LBLlld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:BealKathrynKlld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:IwamotoFabio...lld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:MohileNimish...lld:pubmed
pubmed-article:19167838pubmed:authorpubmed-author:LymberisStell...lld:pubmed
pubmed-article:19167838pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19167838pubmed:day1lld:pubmed
pubmed-article:19167838pubmed:volume75lld:pubmed
pubmed-article:19167838pubmed:ownerNLMlld:pubmed
pubmed-article:19167838pubmed:authorsCompleteYlld:pubmed
pubmed-article:19167838pubmed:pagination156-63lld:pubmed
pubmed-article:19167838pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:meshHeadingpubmed-meshheading:19167838...lld:pubmed
pubmed-article:19167838pubmed:year2009lld:pubmed
pubmed-article:19167838pubmed:articleTitleSafety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.lld:pubmed
pubmed-article:19167838pubmed:affiliationDepartment of Neurosurgery, The Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. gutinp@mskcc.orglld:pubmed
pubmed-article:19167838pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19167838pubmed:publicationTypeEvaluation Studieslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19167838lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19167838lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19167838lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19167838lld:pubmed